A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma
Clinical trial NCT03277105 · COMPLETED
Trial details
- NCT number
- NCT03277105
- Sponsor
- Janssen Research & Development, LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-10-27
- Primary completion
- 2019-06-27
- Enrollment
- 522
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.